


THE JOHNS HOPKINS ACG[®] SYSTEM Celebrating Decades of Impact on Population Health Research and Practice





Identifying patients for care management

- Can occur through multiple methods:
 - referrals by physicians
 - screening statistical algorithms
 - patient surveys
- Increased use of multiple combined approaches to avoid bias in selection by the individual methods

Shadmi & Freund, 2013, Targeting patients for multimorbid care management interventions: the case for equity in high-risk patient identification

© Copyright 2022 Johns Hopkins University

5 • Identify at risk patients – ACG risk profiling tool • Core medical team review • Identify problems, Action list, Suitability for further interventions • Personalised care plan • Discussion and delivery of care plan, Coded and scanned to records • Follow-up • Clinical review (named clinician), Date of review, Response to interventions • Source: Cricket Green Medical Practice Model


10/6/2022

c


METHOD

JOHNS HOPKINS POPULATION HEALTH ANALYTICS

- The predictive models were derived using patient level data
- classification of diagnostic, pharmaceutical and historic utilisation data
- Johns Hopkins ACG System helps to reduce the number of variables and provide measures of multimorbidity
- Logistic and Linear Regressions were undertaken to produce models on the outcomes of hospitalisation within 12/6 months, emergency/unplanned hospitalisation within 12 months, and health care expenditures in the preceding 12 months.
- The models were validated using split-half method and providing AUC analyses to compare different model performance.



ο





Validation Statistics

R-Squared Performance for ACG System Concurrent Risk Models

	R-Squared Modeling Total Cost without Truncation	R-Squared Modeling Total Cost Truncated at \$250,000
Local Age-Gender Risk	0.035	0.056
Local ACG Concurrent Risk	0.229	0.332
Reference ACG Concurrent Risk	0.231	0.333
Concurrent Risk (regression-based)	0.428	0.536

Source: IQVIA, formerly Quintiles/IMS, One IMS Drive, Plymouth Meeting, PA 19462; Subset of the Legacy PharMetrics Adjudicated Claims Detabase containing a national cross-section of managed care plans; population of 3,306,768 Commercial beneficiaries (age under 65 years), 2013-15.

10

12

Validation Statistics (2)

Expected to Actual Cost Ratios by Cost Quintile for ACG System Concurrent Risk Models

	Local Age-Gender Risk Cost Ratio	Local ACG Concurrent Risk Cost Ratio	Reference ACG Concurrent Risk Cost Ratio	Concurrent Risk (regression-based) Cost Ratio
Top 1%	0.05	0.30	0.30	0.53
Top 5%	0.13	0.46	0.46	0.64
Top 20%	0.31	0.71	0.71	0.81
Mid-High	1.85	1.89	1.89	1.57
Mid	4.43	2.77	2.79	2.07
Low-Mid	11.09	4.22	4.46	3.05
Bottom 20%	271.92	14.73	14.76	21.85

11

||


10/6/2022

JOHNS HOPKINS POPULATION HEALTH ANALYTICS

PREDICTIVE HOSPITALIZATION MODELS

Positive Predictive Value	Sensitivity
33.3%	21.2%
32.6%	20.8%
22.4%	14.2%
	33.3% 32.6%

Predictive Model	Persons with Prior Hospitalization	Persons Aged less than 55 without Prior Hospitalization	Persons Aged 55 or older without Prior Hospitalization
IP Hospitalization	.751	.741	.718
IP Hospitalization Six Months	.754	.747	.728
ICU Hospitalization	.805	.757	.754
Injury Hospitalization	.808	.668	.748
Extended Hospitalization	.842	.721	.793



10

10/6/2022

LINEAR MODELS UK '13 VS UK '16

Model	UK 2013 R ²	UK 2016 R ²
Total Cost	0.256	0.271
Drug Cost (based on total cost markers)	0.255	0.362
Drug Cost (based on pharmacy cost markers)	0.355	0.550

All statistics are based on validation model performance

POPULATION HEALTH ANALYTICS

JOHNS HOPKINS

Å

JOHNS HOPKINS POPULATION HEALTH ANALYTICS

BINARY MODELS UK '13 VS UK '16

Model	UK 2013 C-Stat	UK 2016 C-Stat
Total Cost 95th Percentile	0.845	0.873
Drug Cost 95th Percentile (total cost markers)	0.977	0.960
Drug Cost 95th Percentile (pharmacy cost markers)	0.977	0.978
Any Admission next 12 months	0.763	0.780
Any Admission next 6 months	0.782	0.801
Any Admission Length of Stay 12 days+	0.901	0.912
Unplanned (Emergency) Admission	0.773	0.786

All statistics are based on validation model performance

10/6/2022

1 ⊑

Detiente With Consular Cons Nooder	Predictor
Patients With Complex Care Needs:	Age 12-34 year
	Age 35-54 year
The Hotspotter algorithm	Age 55-69 year Age 70-79 year
	Age 80+ year
	Sex (M=1)
Lateratter Definition.	1 Time Limited: Minor
Hotspotter Definition:	2 Time Limited: Minor-Primary Infections
	3 Time Limited: Major
 Problems in 2 or 3 health domains (chronic physical, mental, social 	al) 4 Time Limited: Major-Primary Infections
	5 Allergies
 Multiple acute care visits 	6 Asthma
	7 Likely to Recur: Discrete
 Patient diagnoses over last 12 months (ICPC codes) 	8 Likely to Recur: Discrete-Infections 9 Likely to Recur: Progressive
ratient diagnoses over last 12 months (ICFC codes)	10 Chronic Medical: Stable
 ICPC codes mapped to 32 Aggregated Diagnosis Groups (ADG) using the 	12 Chronic Specialty: Stable-Orthopedic
Johns Hanking ACC System	13 Chronic Specialty: Stable-Ear, Nose, Throat
Johns Hopkins ACG System	14 Chronic Specialty: Stable-Eye
	16 Chronic Specialty: Unstable-Orthopedic
 Probability of being a Hotspotter is calculated based on the patient's 	17 Chronic Specialty: Unstable-Ear, Nose, Throa
	18 Chronic Specialty: Unstable-Eye
age, sex, and combination of ADGs	20 Dermatologic
References:	21 Injuries/Adverse Effects: Minor 22 Injuries/Adverse Effects: Major
	23 Psychosocial: Time Limited, Minor
Girwar et al, Identifying complex patients using Adjusted Clinical Groups risk stratification tool. Am J Manag Care. 2022 Apr 1;28(4):e140-e145. doi: 10.37765/ajmc.2022.88867. PMID: 35420752.	24 Psychosocial: Recurrent or Persistent, Stable
https://pubmed.ncbi.nlm.nih.gov/35420752/	25 Psychosocial: Recurrent or Persistent, Unsta
	26 Signs/Symptoms: Minor
Gawande A. The hot spotters. The New Yorker. January 24, 2011:40-51	27 Signs/Symptoms: Uncertain
https://www.newyorker.com/magazine/2011/01/24/the-hot-spotters	28 Signs/Symptoms: Major
	29 Discretionary
itarfield et al, Multimorbidity and its measurement. Health Policy. 2011 Nov;103(1):3-8.	30 See and Reassure
ttps://www.ncbi.nlm.nih.gov/pubmed/21963153	31 Prevention/Administrative
	32 Malignancy 33 Pregnancy
	34 Dental



CONCLUSIONS


17

JOHNS HOPKINS POPULATION HEALTH ANALYTICS

- Comprehensive person-based records are key
- Local recalibration ensures models are relevant to the population
- Better overall performance than the original models
- New or additional local data variables and definitions
- Traditional modelling techniques (logistic and linear regression) models can be created efficiently, provide good face validity
- Casemix classifications reduce data complexity and provide robust measures of key constructs such as multimorbidity

DISCOSSION PERTINATION PERTINATIO

10/6/2022



Starfield et al, Multimorbidity and its measurement. Health Policy. 201	l Nov;103(1):3-8.
https://www.ncbi.nlm.nih.gov/pubmed/21963153	
 Forrest et al, Medication, diagnostic, and cost information as predictor care management. Am J Manag Care. 2009 Jan; 15(1):41-8. 	rs of high-risk patients in need of
https://www.ncbi.nlm.nih.gov/pubmed/19146363	
 Klaus W. Lemke, Jonathan P. Weiner, Jeanne M. Clark. Development and Inpatient Hospitalization. Med Care. 2012 Feb;50(2):131-9 	IValidation of a Model for Predicting
https://pubmed.ncbi.nlm.nih.gov/22002640/	
 Shannon M.E. Murphy, Heather K. Castro, and Martha Sylvia. Predictive Participant Identification Process for Care Management Programs Usin August 2011, 14(4): 205-210. 	
https://doi.org/10.1089/pop.2010.0005	
 Zachary Predmore, Elham Hatef, Jonathan P.Weiner. Integrating Social Health into Population Health Analytics: A Conceptual Framework and Health Management Vol. 22, No. 6 Dec 2019. 	
https://www.liebertpub.com/doi/abs/10.1089/pop.2018.0151	

21

